期刊文献+

人血清白蛋白融合干扰素α2b体外抑制乙肝病毒的实验研究

Experimental study on inhibition of hepatitis B virus with human serum albumin interferon α2b in vitro
原文传递
导出
摘要 目的:研究长效干扰素人血清白蛋白融合干扰素(HSA-IFNα2b)对HepG2.2.15细胞增殖、凋亡及其HBsAg与HBeAg表达的影响,探讨其体外抑制乙肝病毒的机制。方法:采用SRB法分析HSA-IFNα2b作用HepG2.2.15细胞3,6 d后对其增殖的影响,酶联免疫分析不同剂量HSA-IFNα2b作用不同时间后HepG2.2.15细胞HBsAg与HBeAg的表达水平,Hochest33342、PI双染法观察细胞的凋亡和死亡,Western Blot印迹检测Bcl-2、Bax的表达。结果:HepG2.2.15细胞的增殖在加HSA-IFNα2b作用3,6 d后都有所抑制,细胞培养上清中HBsAg表达明显下降,并与浓度相关,HSA-IFNα2b浓度为10 000 U.mL-1时,培养6 d后HBsAg的抑制率达87%以上。Hochest33342、PI双染结果显示当HSA-IFNα2b浓度在1 250U.mL-1时可见少量的凋亡细胞,凋亡细胞数随着药物浓度的增大而增多,并有少量死亡细胞出现。Western Blot印迹检测随药物浓度的增加Bcl-2的表达降低而Bax的表达增加。结论:HSA-IFNα2b体外可明显抑制HepG2.2.15细胞的增殖及HB-sAg的表达,并可引起HepG2.2.15细胞的凋亡和死亡。 OBJECTIVE To evaluate the effects of a long-acting interferon (HSA-IFNa2b) on the proliferation, apoptosis and expression of HBsAg and HBeAg in HepG 2.2. 15 cells, and to investigate the mechanism of inhibition of hepatitis B virus in vitro. METHODS The cells proliferation was determined by SRB method. The expression levels of HBsAg and HBeAg in supernatant were measured using enzyme-linked dimmunosorbent assay (ELISA). Apoptosis and death were observed by Hochest33342 and PI double staining. Expression of Bcl-2 and Bax proteins were determined with Western blot. RESULTS The results demonstrated that HSA-IFNa2b could inhibit the proliferation of HepG 2. 2. 15 cells. The expression of HBsAg in HepG 2. 2.15 cells was inhibited by HSA-IFNa2b in a time and dose-dependent manner. Treated with 10 000 u.mL^-1 HSAIFNa2b for six days, the inhibitiory rates of HBsAg was above 87%. The Results of Hochest33342 and PI double staining demonstrated HSA-IFNa2b could induce the apoptosis of HepG 2. 2. 15 cells in a dose-dependent manner. The cell death was also occurred at the higher concentration of HSA-IFNa2b. The results of Western blot analysis showed that HSA-IFNa2b could inhibit the expression of Bcl-2, while enhance the expression of Bax. CONCLUSION HSA-IFNa2b could not only significantly inhibit the HBsAg expression and the proliferation of HepG 2. 2. 15 cells, but also induced the apoptosis and death.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第2期100-103,共4页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金(编号:30670589) 卫生部科研基金(编号:wkj2006-2-5) 江苏省医学重点人才项目(编号:RC2007097) 江苏省人事厅“六大人才高峰”(编号:06-B-026)
关键词 人血清白蛋白融合干扰素α2b HEPG2.2.15细胞 HBSAG HBEAG 凋亡 HSA-IFNa2b HepG2. 2. 15 cell HBsAg HBeAg Apotosis
  • 相关文献

参考文献7

  • 1Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C[J].J Control Release, 2001,72(1-3): 217-224.
  • 2Ramon J, Saez V, Baez R, et al. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative [J]. Pharm Res, 2005, 22(8):1374-1386.
  • 3Sung C, Nardelli B, LaFleur DW, etal. An 1FN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates[J].J Interferon Cytokine Res, 2003, 23 (1) : 25-36.
  • 4Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C[J]. Curr Med Res Opin,2009,25(4) :991 1002.
  • 5Sureau C, Romet Lemonne JL, Mullins JI, et al. Production of hepatitis B virus lay a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA[J]. Cell, 1986, 47(1):37-47.
  • 6邢文会,杨萍,汪海霞,杨健良.猕猴体内白蛋白融合干扰素α-2b(HSA-IFNα-2b)的药代动力学研究[J].中国药理学通报,2007,23(9):1156-1160. 被引量:4
  • 7周尧远,蒋孟军,张荣军,蔡刚明,张波,顾晓波,邹美芬.干扰素α-2b对HepG 2.2.15细胞增殖、凋亡及HBsAg与HBeAg表达的影响[J].实用医学杂志,2011,27(5):733-735. 被引量:7

二级参考文献15

  • 1鞠洋,路莉,吴勇杰,高明堂,李文广,闵光宁.ELISA法研究新型重组人肿瘤坏死因子在小鼠体内的药代动力学[J].中国药理学通报,2005,21(7):847-851. 被引量:6
  • 2Shi-He Guan,Mengji Lu,Petra Grünewald,Michael Roggendorf,Guido Gerken,Joerg F Schlaak.Interferon-α response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment[J].World Journal of Gastroenterology,2007,13(2):228-235. 被引量:23
  • 3Osbom B L, Olsen H S, Nardelli B, et al. Phar-macokinetic and pharmacodynamic studies of a human serum albumin-Interferon-α Fusion protein in cynomolgus monkeys[ J]. J Pharmacol Exp Ther, 2002,303 (2) : 540 - 8.
  • 4Bailon P, Palleroni A, Schaffer C A, et al. Rational design of a potent, long-lasting form of interferon : A 40 kDa branchedpolyethylene glycol-conjugated interferon α2a for the treatment of Hepatitis C [ J ]. Bioconjug Chem,2001,12 (2) : 195 - 202.
  • 5Peoinsky R B,Lepage D J, Gil A,et al. Improved Pharmacokinetic propertiesof a polyethylene glycol-modified form of in-terferon-β-1a with preserved in vitro bioactivity[ J]. J Pharmacol Exp Ther, 2001,297(3 ) :1059 -66.
  • 6HGS press release. Human Genome clinical trial of albuferon^TM in treatment-naive patients with chronic hepatitis C [ R ]. February 16, 2005.
  • 7Balan V . Safety, pharmacokinetics and pharmacodynamic results of higher doses of Albuferon (tm) in a phase 1/2 single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C[ R]. 39th Annual Meeting of the European Association for the Study of the Liver, Berlin. April 15, 2004.
  • 8Balan V. A Phase 1/2 Study to Evaluat-e the Pharmacokinetics, Safety, Tolerability, 1-mmunogenicity, and Pharmaeodynamies of A-lbuferon (tm)-alpha in Treatment Experienced S-ubjects with Chronic Hepatitis C[ R]. 54th An-nual Meeting of the American Association f-or the Study of Liver Diseases, Boston. Octo-ber 25, 2003.
  • 9Wills R J. Clinical Pharmacokinetics of lnterferons [ J ]. Clin Pharmacokinet, 1990,19 ( 5 ) :390 - 9.
  • 10周桂楼,蔡刚明,曹国宪,张荣军.病毒性肝炎治疗药物干扰素的研究进展[J].中国医院药学杂志,2008,28(3):226-228. 被引量:10

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部